X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs SUVEN LIFESCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA SUVEN LIFESCIENCES ALEMBIC PHARMA/
SUVEN LIFESCIENCES
 
P/E (TTM) x 16.5 18.9 87.3% View Chart
P/BV x 3.6 3.7 97.3% View Chart
Dividend Yield % 1.1 0.6 171.6%  

Financials

 ALEMBIC PHARMA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
SUVEN LIFESCIENCES
Mar-18
ALEMBIC PHARMA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs664251 264.8%   
Low Rs412155 266.1%   
Sales per share (Unadj.) Rs208.749.1 424.9%  
Earnings per share (Unadj.) Rs31.09.7 319.0%  
Cash flow per share (Unadj.) Rs37.111.4 325.8%  
Dividends per share (Unadj.) Rs5.501.50 366.7%  
Dividend yield (eoy) %1.00.7 138.2%  
Book value per share (Unadj.) Rs144.260.3 239.2%  
Shares outstanding (eoy) m188.52127.28 148.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.64.1 62.4%   
Avg P/E ratio x17.420.9 83.2%  
P/CF ratio (eoy) x14.517.8 81.4%  
Price / Book Value ratio x3.73.4 110.9%  
Dividend payout %17.715.4 114.9%   
Avg Mkt Cap Rs m101,46125,825 392.9%   
No. of employees `000NA1.1 0.0%   
Total wages/salary Rs m7,467613 1,218.7%   
Avg. sales/employee Rs ThNM5,832.6-  
Avg. wages/employee Rs ThNM571.5-  
Avg. net profit/employee Rs ThNM1,153.8-  
INCOME DATA
Net Sales Rs m39,3476,253 629.3%  
Other income Rs m94233 40.3%   
Total revenues Rs m39,4416,485 608.2%   
Gross profit Rs m8,7361,982 440.8%  
Depreciation Rs m1,152213 540.7%   
Interest Rs m18446 397.6%   
Profit before tax Rs m7,4931,955 383.3%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,568718 218.2%   
Profit after tax Rs m5,8441,237 472.5%  
Gross profit margin %22.231.7 70.0%  
Effective tax rate %20.936.7 56.9%   
Net profit margin %14.919.8 75.1%  
BALANCE SHEET DATA
Current assets Rs m19,5775,622 348.2%   
Current liabilities Rs m14,8961,168 1,275.8%   
Net working cap to sales %11.971.2 16.7%  
Current ratio x1.34.8 27.3%  
Inventory Days Days9081 110.2%  
Debtors Days Days4536 126.2%  
Net fixed assets Rs m27,0973,325 815.0%   
Share capital Rs m377127 296.2%   
"Free" reserves Rs m26,8117,547 355.3%   
Net worth Rs m27,1887,674 354.3%   
Long term debt Rs m4,99314 35,920.9%   
Total assets Rs m47,7789,135 523.0%  
Interest coverage x41.743.2 96.5%   
Debt to equity ratio x0.20 10,139.0%  
Sales to assets ratio x0.80.7 120.3%   
Return on assets %12.614.0 89.8%  
Return on equity %21.516.1 133.4%  
Return on capital %23.626.0 90.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,4535,066 384.0%   
Fx outflow Rs m6,0652,001 303.1%   
Net fx Rs m13,3883,065 436.8%   
CASH FLOW
From Operations Rs m8,120699 1,160.9%  
From Investments Rs m-7,556-6 123,868.9%  
From Financial Activity Rs m590-577 -102.3%  
Net Cashflow Rs m1,153116 991.7%  

Share Holding

Indian Promoters % 74.1 63.4 116.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.0 -  
FIIs % 9.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 36.5 38.1%  
Shareholders   49,328 37,287 132.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  WOCKHARDT  GSK PHARMA  PLETHICO PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS